Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
... and the octreotide implant (in development for acromegaly and carcinoid syndrome), two of Indevus' primary ... FDA for marketing and sale for the treatment of acromegaly or carcinoid syndrome. The tender offer is ... pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for ...Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results
... Endo in the future upon achievement of certain milestones related to NEBIDO(R) (in development for hypogonadism) and octreotide (in development for acromegaly and carcinoid syndrome), two of the Company's primary product candidates. The acquisition will be effected by means of a tender offer for all the ...Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
... NEBIDO(R) for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. About Endo Pharmaceuticals Endo Pharmaceuticals is a specialty pharmaceutical ...Options Improving for Patients With Acromegaly and Gigantism
... Medicine. “Despite the improvements, acromegaly remains a very challenging and very complex ... of our support groups.” Nearly all cases of acromegaly are caused by tumors of the pituitary gland. More than 90 percent of patients with acromegaly have a slow-growing type of tumor that is found ...FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
... NEBIDO(R) for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Safe Harbor Statement This press release contains forward-looking statements ...Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
... NEBIDO(R) for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. PRO 2000 PRO 2000 (a naphthalene sulfonate polymer) is under development as a ...Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
... for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and the octreotide implant for acromegaly and carcinoid syndrome. About Pagoclone Pagoclone is a novel, non-benzodiazepine, selective GABA-A receptor agonist. In clinical studies in ...ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
... is a second-generation antisense drug designed to lower blood IGF-I levels and is entering pre-clinical development as a potential treatment for acromegaly and vision disorders. ATL/TV1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL1101 is a second-generation ...Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
... patented Hydron technology utilized in the Company's currently approved and marketed products SUPPRELIN(R) LA and VANTAS(R). About Acromegaly acromegaly is a chronic hormonal disorder that occurs when a pituitary tumor produces excess growth hormone, or GH. It most commonly affect middle- aged adults, ...IGF-I IRMA Test (With Extraction)
Description:... many of the actions of GH [6]. In GH deficiency, malnutrition [4] and GH-receptor deficiency [7], serum IGF-I levels are low. Conversely, in acromegaly (GH excess) serum IGF-I levels are elevated [4,6]. Measurement of IGF-I levels in serum is a useful diagnostic test for the clinical evaluation of ...IGF-I ELISA Test (With Extraction)
Description:... many of the actions of GH [6]. In GH deficiency, malnutrition [4] and GH-receptor deficiency [7], serum IGF-I levels are low. Conversely, in acromegaly (GH excess) serum IGF-I levels are elevated [4,6]. Measurement of IGF-I levels in serum is a useful diagnostic test for the clinical evaluation of ...IGF-I IRMA Test (Non-Extraction)
Description:... many of the actions of GH [6]. In GH deficiency, malnutrition [4] and GH-receptor deficiency [7], serum IGF-I levels are low. Conversely, in acromegaly (GH excess) serum IGF-I levels are elevated [4,6]. Measurement of IGF-I levels in serum is a useful diagnostic test for the clinical evaluation of ...IGF-I ELISA Test (Non-Extraction)
Description:... many of the actions of GH [6]. In GH deficiency, malnutrition [4] and GH-receptor deficiency [7], serum IGF-I levels are low. Conversely, in acromegaly (GH excess) serum IGF-I levels are elevated [4,6]. Measurement of IGF-I levels in serum is a useful diagnostic test for the clinical evaluation of ...Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
... of PRO 2000 -- Phase III Clinical Trial of Octreotide Implant for acromegaly Initiated Business Development -- Licensing of European Rights ... HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. About ...Indevus Pharmaceuticals Announces Release of 2008 Annual Report
... NEBIDO(R) for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Contact: Michael W. Rogers EVP and Chief Financial Officer (781) ...Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
... NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained ...Indevus and FDA Agree on Path Forward for NEBIDO(R)
... for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and the octreotide implant for acromegaly and carcinoid syndrome. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains ...Indevus Announces Private Placement of $105 Million of Non-Recourse Notes
... for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and the octreotide implant for acromegaly and carcinoid syndrome. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains ...